Ahmedabad based Cadila Pharmaceuticals is eyeing to achieve revenue worth Rs 100 crore in the first year, from the sale of its patented combination drug, Policap.

The company believes that Policap has the potential of becoming a blockbuster drug and revenue earnings from it should be more than Rs 100 crore per annum. The firm has scheduled to launch the drug, by the middle of next month.

It should be noted that the company has already applied to Drug Controller General of India, to seek permission regarding the launch of drug in the country, and company officials are hopeful that it may get the nod, by mid-June.

Policap is a combination of three common anti-hypertensive drugs along with aspirin and statin (cholesterol lowering drug), which used to reduce risk of heart attacks. The company has been tested the drug on over 200 patients in 50 centers across the country.

The company claims that the risk of heart attack can be decreased by 50 per cent with the use of this drug.

On successful launch of Policap in India, the company intends to apply for regulatory approvals to introduce the drug in the US and other developed markets.

Reports suggested that Cadila is also looking at global tie-ups with multinationals to launch the drug in overseas markets.